Hafnia Alvei Infection: Pathogenesis, Diagnosis, and Resistance

Hafnia alvei is a gram-negative bacterium in the Enterobacteriaceae family that causes opportunistic infections ranging from gastroenteritis to bloodstream infections, primarily in people who are already hospitalized or immunocompromised. Despite being an uncommon clinical pathogen, it presents a tangle of challenges: it is frequently misidentified as other bacteria, it carries intrinsic resistance to several commonly used antibiotics, and its actual role in causing disease remains debated for certain infection types. Understanding how this organism operates, how clinicians identify it, and which drugs still work against it matters both for patient care and for the broader effort to track resistance in lesser-known pathogens.

What Hafnia Alvei Is and Where It Lives

Hafnia alvei is a rod-shaped, facultatively anaerobic bacterium that thrives in a surprisingly wide range of environments. It has been isolated from soil, water, sewage, food products, and the gastrointestinal tracts of humans and animals. A comprehensive review of the genus noted that Hafnia bacteria are occasionally implicated in both intestinal and extraintestinal infections, but also acknowledged numerous gaps in understanding its ecological habitats and population genetics.¹ It is a commensal organism in the gut of many healthy people, which complicates the picture when it shows up in stool cultures from someone with diarrhea.

The genus Hafnia is not as uniform as it might seem. Genetic studies have revealed two distinct genomic groups within what was traditionally called “Hafnia alvei.” These two groups, now recognized as Hafnia alvei and Hafnia paralvei, cannot be reliably told apart by most standard biochemical tests. Early work using partial 16S rRNA gene sequencing found that markers like motility and carbohydrate fermentation patterns did not cleanly separate the two groups, though malonate utilization came closest as a single discriminating test.² This genetic split has practical consequences for diagnosis and treatment, because the two species may differ in virulence and resistance profiles.

How It Causes Disease

For an organism that flies under the clinical radar, Hafnia alvei has a surprisingly rich toolkit for surviving in and potentially harming a human host. Its virulence mechanisms fall into a few broad categories: attachment and biofilm formation, iron acquisition, endotoxin production, and mucosal damage.

One of the more clinically relevant traits is biofilm formation. A study of a human clinical isolate found that the strain produced cellulose-based biofilms, with the process ramping up at lower temperatures around 28°C compared to body temperature. The ability to stick to abiotic surfaces like medical devices and form protective biofilm communities likely helps Hafnia alvei persist in hospitals and food-processing facilities, increasing the chance it encounters vulnerable patients.³ Draft genome analysis of another strain identified additional genetic elements supporting this picture, including the tad locus (essential for biofilm formation) and a widespread colonization island that equips the bacterium for gut colonization.⁴

Iron is scarce inside the human body because the host actively sequesters it to starve invading bacteria. Hafnia alvei gets around this by producing siderophores, small molecules that scavenge iron from the surrounding tissue. Interestingly, the siderophores Hafnia secretes are unusual. Unlike most members of the Enterobacteriaceae family, which typically produce enterobactin or aerobactin, Hafnia alvei strains secrete a siderophore type that matches neither.⁵ The identity of this siderophore is still not fully characterized, which is a good example of how understudied this organism remains.

Like other gram-negative bacteria, Hafnia alvei’s outer membrane contains lipopolysaccharide (LPS), whose lipid A component is the endotoxin responsible for triggering inflammation. Structural studies showed that Hafnia alvei lipid A closely resembles that of Escherichia coli, which is the classic potent endotoxin. The bacteria can also modify their lipid A by adding a palmitate group, a change that in other organisms has been linked to evading host immune defenses.⁶ The core region of Hafnia’s LPS also turns out to be more diverse than expected: some strains share core structures with E. coli, others with Salmonella, and some have a unique outer-core arrangement featuring a Kdo-containing trisaccharide not seen in the classical scheme.⁷⁸ This molecular diversity across strains matters for serological typing and for understanding why immune responses to Hafnia can be inconsistent.

What Infections It Actually Causes

The clinical picture of Hafnia alvei infection splits into two categories: gastrointestinal and extraintestinal disease. Both are uncommon, and the evidence for each comes mostly from case reports and small series rather than large epidemiological studies.

The gastrointestinal role has been debated for decades. A landmark study isolated Hafnia alvei as the sole pathogen from a 9-month-old infant with watery diarrhea. The strain caused diarrhea in the majority of adult rabbits tested, and electron microscopy revealed a pattern of “attaching and effacing” damage to intestinal cells, the same mechanism used by enteropathogenic E. coli. Bacteria adhered to the surface of gut cells, destroyed the microvillus border, and formed pedestal-like structures at attachment sites.⁹ Other reports described acute gastroenteritis in children attributed to Hafnia alvei.¹⁰¹¹ Still, the genus review noted that laboratory data specifically linking Hafnia to gastroenteritis remain thin, and many researchers are cautious about labeling it a true enteric pathogen outside of specific virulent strains.²

Extraintestinal infections are better documented and clinically more concerning. A review of Hafnia alvei extraintestinal infections found cases of hospital-acquired urinary tract infections, community-acquired cholangitis, cholecystitis, appendicitis, psoas abscess, and prosthetic endocarditis.¹² In young infants without obvious underlying conditions, Hafnia has caused sepsis combined with urinary tract infection, a reminder that the organism can occasionally behave aggressively even outside the typical high-risk groups.¹³ In the hospital setting, urinary tract infections, respiratory tract infections, and wound infections are the most frequent presentations, with classic risk factors including prolonged ICU stays, cardiovascular surgery, shock, and advanced age.¹⁴

Who Is Most at Risk

A population-based surveillance study from a large Canadian health region offers the best available snapshot of who develops Hafnia alvei infections. The median age of patients was 69 years, and the rate climbed steeply with age, peaking at 60 per 100,000 per year in people over 90. Women accounted for about three-quarters of cases overall, with isolation rates roughly three times higher in females than males. Men, however, were much more likely to have hospital-acquired isolates: about 59% of male cases were from hospitalized patients, compared to 25% of female cases.¹⁵ The high proportion of female community-acquired cases likely reflects urinary tract infections, a common source for Hafnia isolates in outpatient settings. The age and sex profile suggests clinicians should keep Hafnia on the differential particularly in elderly patients with urinary or biliary symptoms, even when they are not in the hospital.

The Identification Problem

One of the biggest practical headaches with Hafnia alvei is that clinical labs routinely misidentify it. Conventional biochemical methods and older automated systems have confused Hafnia with Serratia, Escherichia, Citrobacter, Yokenella, Obesumbacterium, and even Salmonella.¹⁶ A case report documented a mucoid Salmonella strain repeatedly misidentified as Hafnia alvei by the Vitek GNI+ automated card system, which could have led to inappropriate treatment for a far more consequential pathogen.¹⁷ Errors in both directions are harmful: calling Hafnia something else can delay appropriate therapy, and calling Salmonella “Hafnia” can mask a pathogen that demands public health action.

Distinguishing Hafnia alvei from Hafnia paralvei adds another layer of difficulty. Of the 46 biochemical tests evaluated in one study, over 40% gave variable results within the genus. Malonate utilization alone correctly assigned about 90% of isolates to the right DNA group, making it the single best conventional discriminator.¹⁸ A more refined panel of four tests, including malonate utilization, fermentation of salicin and d-arabinose, and expression of β-glucosidase activity, was later shown to correctly assign every tested strain to either H. alvei or H. paralvei.¹⁹

Molecular methods have improved matters considerably. Partial 16S rRNA gene sequencing can separate the two species, and studies of clinical isolates with suspected pathogenic traits identified specific biochemical profiles, such as negative reactions in 2-ketogluconate and histidine assimilation and a positive reaction in 3-hydroxybenzoate assimilation, that may help flag pathogenic strains in routine lab work.²⁰ MALDI-TOF mass spectrometry, now standard in many clinical and veterinary labs, has proven reliable for identifying Hafnia alvei and is increasingly the go-to method in settings that have access to it.²¹

Antibiotic Resistance and Treatment Challenges

Hafnia alvei carries a chromosomal AmpC-type cephalosporinase, a built-in enzyme that breaks down certain beta-lactam antibiotics. This is not acquired resistance picked up from the environment; it is part of the organism’s native genetic makeup. In most isolates, this enzyme is inducible: it sits at low levels until the bacterium encounters a beta-lactam drug, at which point production ramps up. The regulation involves the interplay of AmpR (a transcriptional activator) and AmpD (a regulator that keeps production in check). When this regulatory system malfunctions, typically through mutations in ampD, the result is constitutive high-level cephalosporinase production that confers resistance to extended-spectrum cephalosporins.²² A study of clinical isolates confirmed this two-tier pattern: some showed low-level, inducible resistance while others displayed high-level, constitutive cephalosporinase production.²³

The practical fallout is that treating Hafnia alvei infections with first- and second-generation cephalosporins is unreliable. Third-generation cephalosporins work in many cases, but there is always the concern that treatment pressure could select for derepressed mutants producing the enzyme at high levels. One recent study of adult bacteremia patients found that resistance did not develop in any of the ten patients treated with third-generation cephalosporins, a reassuring finding, though the numbers are small.²⁴

Beyond the intrinsic AmpC enzyme, Hafnia alvei can acquire resistance to additional drug classes. Comparative genomic analysis identified resistance genes covering aminoglycosides, beta-lactams, bacitracin, cationic antimicrobial peptides, fluoroquinolones, and rifampin across the genus.²⁵ Perhaps more alarming is a report of a Hafnia alvei clinical isolate producing OXA-48, a carbapenemase that breaks down carbapenems, the drugs often considered last-resort options for gram-negative infections. The gene was likely acquired by horizontal transfer from an Enterobacter cloacae strain previously isolated from the same patient.²⁶ While this remains an isolated report, it signals that Hafnia can participate in the same resistance gene-sharing networks that make other Enterobacteriaceae so worrisome.

Hafnia Alvei in Food and Cheese Ripening

Hafnia alvei leads a double life. While clinicians worry about it as an opportunistic pathogen, food scientists know it as a routine participant in fermented foods, especially cheeses. The bacterium contributes to ripening by producing volatile sulfur compounds and other aroma molecules that shape flavor. In experimental smear soft cheeses, Hafnia alvei significantly influenced the production of volatile aroma compounds, even though it was subdominant to the other bacteria by the end of ripening.²⁷ Hafnia also uses quorum-sensing communication to coordinate enzymatic activities in fermented food environments, though this same metabolic versatility means it can produce biogenic amines, compounds that in high concentrations can cause food-poisoning-like symptoms in sensitive individuals.²⁸

The Probiotic Angle

In what might seem like a surprising twist for a bacterium associated with infection, a specific strain of Hafnia alvei (HA4597) is being developed as a probiotic for weight management. The rationale comes from the observation that this strain produces a protein called ClpB that mimics a satiety hormone, potentially reducing appetite. In obese mice, oral administration of this strain reduced body weight gain, fat mass, and food intake.²⁹ A multicenter randomized, double-blind, placebo-controlled trial in overweight human subjects found that about 55% of those taking the Hafnia strain met the primary weight-loss endpoint, compared to about 41% in the placebo group. The supplement group also reported increased feelings of fullness, greater loss of hip circumference, and lower fasting blood sugar at 12 weeks. Clinical and biological tolerance was good.³⁰

It is worth noting the tension here. The same species associated with nosocomial infections and antibiotic resistance is being given to people deliberately. The probiotic work uses a carefully selected commensal strain, and the safety data so far look clean. But the coexistence of pathogenic and probiotic strains within a single species underscores how variable Hafnia alvei really is, and why blanket statements about the organism being “dangerous” or “safe” miss the point entirely. Strain-level characterization matters enormously, and that kind of fine-grained analysis is something the field is still catching up on.

Why Hafnia Alvei Remains Understudied

For all the complexity described above, Hafnia alvei occupies an awkward niche in microbiology. It is too rare to command the research funding and clinical attention devoted to organisms like E. coli, Klebsiella, or Pseudomonas. Its status as a commensal muddies the waters: when it shows up in a culture, clinicians often wonder whether it is the cause of an infection or just a bystander. The fact that it is often misidentified makes surveillance data unreliable, so we probably do not have an accurate count of how often it truly causes disease. And the genus itself is heterogeneous, with Hafnia paralvei only recently being separated out, meaning that older studies lumped two potentially distinct organisms together.

What makes this organism worth paying attention to is not its raw frequency but what it represents: a member of a family notorious for acquiring and spreading resistance genes, living in environments (hospitals, food supply chains, the human gut) that offer ample opportunity for gene exchange with more dangerous relatives. The emergence of carbapenem-resistant Hafnia, even in a single reported case, illustrates that low-profile pathogens can serve as quiet reservoirs for the resistance mechanisms that clinicians fear most in better-known bacteria.